



## Free services through EURIPRED

**EURIPRED (European Research Infrastructures for Poverty Related Diseases) is a collaborative infrastructure programme with the objective to reinforce the knowledge infrastructure across diseases. The programme focuses on vaccines, drugs and microbicides to combat poverty related diseases such as Tuberculosis, HIV, Malaria, Hepatitis B and Hepatitis C. In this context, EURIPRED supports European scientists with free access to reference reagents, services and trainings.**

A series of calls are launched throughout the project, including calls for applications for:

- **Access to biological materials and reference reagents/ standards**, facilitated by the National Institute of Biological Standards and Control (NIBSC), UK;
- **Access to vaccine adjuvant & formulation studies**, facilitated by the Vaccine Formulation Laboratory of the University of Lausanne, Switzerland;
- **Access to peptide microarray facility for screening & evaluation**, facilitated by JPT Peptide Technologies, Germany.

A detailed overview of the services can be found on the EURIPRED website [www.euripred.eu/free-services](http://www.euripred.eu/free-services).

### Free of charge for European scientists

Application for free services will be selected under a peer-reviewed process. Only European user groups (from EU Member States or Associated States) can apply for the free services, and only to EURIPRED Service infrastructures outside their own country. For scientists based in countries outside the EU Member States or its Associated States, access is subject to a range of charges according to the service requested.

### Selection criteria

Scientific excellence is the main selection criterion, i.e. objectives, feasibility, innovation, quality and record of investigators, quality of the proposed methodology, potential impact, compliance with national and international standards of research are considered to be sub-components of scientific excellence.

The services are not restricted to any diseases in particular but will be prioritised to poverty related diseases, such as HIV, TB, malaria and hepatitis B/C.

### Application deadlines

EURIPRED operates a series of calls from Oct 2014 to Jul 2017. Applications may be submitted at any time and will be processed at a pre-defined deadline for each call of applications. The deadlines can be found on the website [www.euripred.eu/free-services/call-schedule](http://www.euripred.eu/free-services/call-schedule).

### Contact information

Requests to additional reference reagents, services, and trainings are welcome and can be directed to the EURIPRED project team: [yann.leduff@nibsc.org](mailto:yann.leduff@nibsc.org).



*EURIPRED is co-funded with € 8.5 million by the European Commission. Scientists from 17 research partners in 10 countries collaborate in this programme. The project started in November 2013, is a 4-year project and has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No 312661. The project is coordinated by Dr Mei Mei Ho of NIBSC-MHRA, UK.*

[www.euripred.eu](http://www.euripred.eu)